Filing Flows › Companies › Iovance Biotherapeutics › Earnings quality
Iovance Biotherapeutics earnings quality score
How much of the reported profit is backed by cash, and how many markers of managed earnings the filings show
Score68 / 100 · grade B · rank 416 of 1027
Iovance Biotherapeutics (IOVA) scores 68 of 100 for earnings quality, grade B: rank 416 of 1027 companies and 37 of 126 in health. It loses the most points on adjusted earnings far below GAAP (more than ten times apart), discretionary accruals of +4.6% of assets (modified Jones), larger than most, Piotroski F-score 4 of 9. It earns full or near-full marks for Beneish M-score -2.54: clean (below −2.22), profit about as variable as cash flow (smoothness 1.09). Revenue grew 51% in the year: fast growth raises accruals, the Beneish and Dechow scores and the C-score by construction, so a growing company scores lower than a steady one with the same accounting.
What earned and lost points
| Component | What the filings show | Points | Of |
|---|---|---|---|
| Accruals | accruals of -9.7% of assets, lower than 83% of companies (profit backed by cash) | 17 | 20 |
| Beneish M-score | Beneish M-score -2.54: clean (below −2.22) | 15 | 15 |
| Dechow F-score | Dechow F-score 1.39 (above normal) | 11 | 15 |
| Montier C-score | Montier C-score 1 of 6 checks failed | 12 | 15 |
| Discretionary accruals | discretionary accruals of +4.6% of assets (modified Jones), larger than most | 4 | 10 |
| Piotroski F-score | Piotroski F-score 4 of 9 | 4 | 10 |
| Non-GAAP gap | adjusted earnings far below GAAP (more than ten times apart) | 0 | 10 |
| Earnings smoothness | profit about as variable as cash flow (smoothness 1.09) | 5 | 5 |
How the score is built
Eight published measures, each scored against the whole universe or on its own scale and weighted: accruals 20, discretionary accruals 10, Beneish M 15, Dechow F 15, Montier C 15, Piotroski F 10, the non-GAAP gap 10, smoothness 5. A measure that cannot be computed (Beneish for a bank, say) drops out and the rest is rescaled, so every company is scored on what applies to it.
Every company ranked → The full quality workbench, live → Iovance Biotherapeutics: cash flow →
Computed from the companies’ own XBRL filings (latest fiscal year) by published formulas; a statistical screen, not an audit or an accusation. A low score means the reported profit shows more of the markers of managed or low-quality earnings than its peers. Not investment advice.